Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan.

@article{Cangiano1992EatingBA,
  title={Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan.},
  author={Carlo Cangiano and Fabrizio Ceci and Antonia Cascino and Maria del Ben and Alessandro Laviano and Maurizio Muscaritoli and Fabiola Antonucci and Filippo Rossi‐Fanelli},
  journal={The American journal of clinical nutrition},
  year={1992},
  volume={56 5},
  pages={
          863-7
        }
}
Previous observations have shown that oral administration of 5-hydroxytryptophan (5-HTP) without dietary prescriptions causes anorexia, decreased food intake, and weight loss in obese subjects. To confirm these data over a longer period of observation and to verify whether adherence to dietary restriction could be improved by 5-HTP, 20 obese patients were randomly assigned to receive either 5-HTP (900 mg/d) or a placebo. The study was double-blinded and was for two consecutive 6-wk periods. No… 
View on PubMed
doi.org
104 Citations
Highly Influential Citations
5
Background Citations
27
Methods Citations
3
Results Citations
3

Figures and Tables from this paper

104 Citations

The Effects of 5-HTP on Body Composition: An 8-Week Preliminary RCT.

Based on the limited data from this investigation, daily supplementation with 100 mg of 5-HTP may affect body composition.

Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin dependent diabetic patients

Data confirm the role of the serotonergic system in reducing energy intake, by predominantly inhibiting carbohydrate intake, and suggest that 5-HTP may be safely utilized to improve the compliance to dietary prescriptions in non-insulin dependent diabetes mellitus.

Relationship between the absorption of 5-hydroxytryptophan from an integrated diet, by means of Griffonia simplicifolia extract, and the effect on satiety in overweight females after oral spray administration

It is shown that the 5-Hydroxytryptophan present in the Griffonia extract, administered via spray to the oral cavity, is adequately absorbed, as confirmed by the increase in 24-h urinary 5-HIAA, and that the supplementation of the diet of overweight women with 5-hydroxytiptophan increases the feeling of satiety associated with a decrease in BMI.

The E ffec ts Of A Structured Lifestyle Intervention Program In Conjunction With Dietary Supplementation On Weight Loss And Risk F

The objective of this study was to determine the effects of a structured weight loss program that included hypocaloric diet, exercise and dietary supplementation, on weight loss, metabolic syndrome…

Satiety and amino-acid profile in overweight women after a new treatment using a natural plant extract sublingual spray formulation

5HTP-Nat Exts may be safely used to treat the problem of appetite control in overweight women during a weight loss program, and all the amino acids evaluated after a single administration were found to be similar.

Dexfenfluramine, Fluoxetine, and Weight Loss Among Female Carbohydrate Cravers

Obese females who consumed at least 30% of their daily calories from CHO-rich snacks were treated with dexfenfluramine or placebo and results suggest that weight loss following treatment with serotoninergic drugs may relate to a selective decrease in CHO appetite.

Efficacy and safety of low-carbohydrate diets: a systematic review.

There is insufficient evidence to make recommendations for or against the use of low-carbohydrate diets, particularly among participants older than age 50 years, for use longer than 90 days, or for diets of 20 g/d or less of carbohydrates.

Energy Balance Model and Sites of Drug Action in the Host

In a recent clinical trial, 811 individuals who were assigned to one of four diets with different levels of fat, protein, and carbohydrate all lost the same amount of weight over 6 and 24 months, showing again that calories do count and that the composition of the diet does not.

Drug treatment of the overweight patient.

Three medications with approval for long-term use in the treatment of obesity are currently available and significantly increase weight loss compared with placebo; weight loss with these drugs reaches a nadir between 20 and 28 weeks; weight lost, averaged 8%-10%, with the placebo contributing 4%-6% of that.

Changes in Plasma Amino Acid Levels Do Not Predict Satiety and Weight Loss on Diets with Modified Macronutrient Composition

An increase in either carbohydrate or protein intake increases satiety and leads to significant weight loss, however, these effects are not mediated by an increase in plasma concentration of Trp or the Trp:LNAA ratio.
...

References

SHOWING 1-10 OF 22 REFERENCES

Carbohydrate craving in obese people: Suppression by treatments affecting serotoninergic transmission

Observations show that some obese people do consume carbohydrate-rich snacks frequently and preferentially, and that this behavior can sometimes be diminished by treatments thought to enhance serotonin's release (fenfluramine) or synthesis (tryptophan).

INTERNATIONAL TRIAL OF LONG-TERM DEXFENFLURAMINE IN OBESITY

Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity.

The majority of patients tolerate fenfluramine satisfactorily, although some patients may have to discontinue the drug because of troublesome gastro-intestinal problems, diarrhoea, drowsiness or dizziness, and it probably has little abuse potential.

A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters.

Patients treated with fluoxetine plus behavior modification lost significantly more weight than those treated with placebo plusbehavior modification, however, the drug did not appear to have a differential benefit for binge-eaters.

Medial hypothalamic serotonin: role in circadian patterns of feeding and macronutrient selection

Selective increase in carbohydrate intake by rats treated with 8-hydroxy-2-(di-n-propylamino)-tetraline or buspirone.

Fenfluramine and fluoxetine spare protein consumption while suppressing caloric intake by rats.

Observations indicate that two distinct brain mechanisms, sensitive to different drugs, underlie the elective consumption of protein and calories.

Plasma tryptophan and anorexia in human cancer.

Serotonin and Appetite

  • G. Curzon
  • Biology
    Annals of the New York Academy of Sciences
  • 1990
5-HT1A agonists (8-OHDPAT, buspirone, gepirone, etc.) stimulate intake in freely feeding rats, probably by activating autoreceptors on the cell bodies of 5- HT neurons so that 5-HT release at terminals is decreased and feeding in previously food-deprived rats is decreased.

The effect of 5‐hydroxytryptophan on food intake and on the anorexic action of amphetamine and fenfluramine

Findings provide further evidence for the role of 5‐hydroxytryptamine (5‐HT), in the anorexic effect of fenfluramine, and suggest that a 5‐HT mechanism, inhibitory for feeding, produces particularly severe suppression of food intake in rats with lateral hypothalamic lesions.